Clinical Trials Logo

Clinical Trial Summary

Inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, immune-mediated disease increasingly prevalent in youth. Patients with IBD experience pain, fatigue, altered bowel habits, psychological distress, and reduced quality of life. Regardless of disease activity, persistent pain and psychiatric comorbidities both have a negative impact on quality of life. Alongside standard pharmacologic and nutritional therapies, clinical hypnosis is a complementary therapy that may improve physical and psychosocial outcomes in these patients. Clinical hypnosis consists of guiding the patient into a relaxed and focused state and providing therapeutic suggestions to induce desired physiologic and psychologic change. Children and adolescents are excellent candidates for hypnosis by virtue of their vivid imaginations. Hypnosis is effective in management of functional abdominal pain, irritable bowel syndrome, anxiety, chronic pain, and distress related to medical procedures. To date, there are no clinical trials that evaluate the effects of hypnosis in pediatric patients with IBD, but there is strong conceptual support for its role in improving pain and psychological distress in these patients. In addition to genetic, environmental, and microbial influences, a growing body of evidence supports the role of a dysregulated brain-gut axis and chronic stress in IBD. Animal and human studies demonstrate the effect of stress on the immune system and gastrointestinal tract. Studies show that the benefits of hypnosis may extend to its role in increasing vagal tone and regulating the immune system via the brain-gut axis. Adults with UC receiving a hypnosis intervention demonstrated improved remission and decreased inflammatory markers. Case series suggest that children with inflammatory bowel disease benefit from hypnosis, and it can be safely and easily delivered via audio recordings. Patients with IBD are interested in integrative therapies to reduce symptoms and improve quality of life, and a biopsychosocial approach is essential in their care. The addition of hypnosis may improve outcomes through influence on stress, inflammation, coping, symptom perception, and quality of life.

The investigators hypothesize that pediatric patients with CD participating in a clinical hypnosis intervention as an adjunct to standard of care will report improved quality of life compared to a waitlist control group. The specific aims of the study are as follows: (1) To implement hypnosis as an adjunctive therapy in adolescents with CD. (2) To evaluate the impact of hypnosis in CD on measures of quality of life. (3) To evaluate the impact of hypnosis in CD on pain, depression, anxiety, sleep, and coping.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03809195
Study type Interventional
Source Vanderbilt University Medical Center
Contact
Status Completed
Phase N/A
Start date February 14, 2019
Completion date May 1, 2020

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02522169 - TOPIT; Trough Level Optimized Pediatric Inflammatory Bowel Disease Therapy: A Multicenter Study Comparing Effectiveness of Trough Level Optimized Infliximab Maintenance Therapy With Standard Dosing Regimen of Pediatric Patients With Crohn's Disease N/A
Completed NCT03194529 - FMT in Pediatric Crohn's Disease Phase 1/Phase 2
Recruiting NCT05673278 - Non-Invasive Monitoring Through Bowel Ultrasound in Paediatric Inflammatory Bowel Disease Study
Completed NCT05591976 - Exercise Training in Youth With Inflammatory Bowel Disease N/A
Not yet recruiting NCT05842564 - Autophagy in Paediatric Crohn's Disease N/A
Terminated NCT03827109 - Peer Mentoring to Improve Self-management in Youth With IBD N/A
Completed NCT04018599 - Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS Phase 1
Completed NCT03378167 - PediCRaFT: Pediatric Crohn's Disease Fecal Transplant Trial Phase 1
Recruiting NCT04186247 - Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD) Phase 2
Enrolling by invitation NCT05918562 - Efficacy of a Low Fiber Diet for Pediatric Colonoscopy Prep N/A